It is big news that the FDA approved a new drug to address NVP. The drug will be available by the end of May, so it is important to educate OB-GYN practitioners about the treatment.
New Orleans, LA (PRWEB) April 29, 2013
Medavera, Inc. today announced an accredited live educational symposium to address care options for the condition of nausea and vomiting of pregnancy (NVP). The program will include a discussion on a recently approved fixed dose combination containing an antihistamine and vitamin B6 analog, which is the first drug the FDA has approved to treat morning sickness in the United States in over 30 years. The symposium, entitled "Nausea & Vomiting of Pregnancy: Cases for Pharmacological Consideration," will be held in New Orleans, Louisiana on Monday, May 6, 2013, during the time period of the American College of Obstetricians and Gynecologists (ACOG) 61st Annual Clinical Meeting.
The program, which will offer educational content developed by expert faculty and Medavera, is accredited by Educational Review Systems. The educational material being presented is designed to give obstetricians, gynecologists and other healthcare professionals who care for pregnant women information on how to provide relief for patients experiencing NVP.
Research shows that 70 to 85 percent of pregnant women endure NVP, with symptoms ranging in severity. 1) The condition impacts roughly half of mothers during early pregnancy, and 35% of affected women experience clinically significant nausea and vomiting, “resulting in lost work time and negatively affecting family relationships.” 2) Because there have been few treatments approved in the last 30 years, healthcare professionals have had limited options for effectively addressing NVP and the resulting health risks.
The symposium will take place May 6, 2013, from 5:30 pm – 7:00 pm at the Windsor Court Hotel, located at 300 Gravier Street, New Orleans, LA. Medical professionals are invited to the Gallery on the 4th floor of the hotel, where a wine and appetizer reception will be held along with the educational program. Duchesnay USA is providing the educational grant support needed to fund the accredited symposium, which will offer physicians and nurses the opportunity to earn 1.5 hours of continuing education (CE) credit.
The program will feature a faculty of leading experts on pregnant women’s and fetal health issues:
- Ralph W. Hale, MD, Past Executive Vice President of The American College of Obstetricians and Gynecologists
- Gary D.V. Hankins, MD, Garland D. Anderson, MD, Distinguished University Chair in Maternal Fetal Medicine, Professor and Chairman, Department of Obstetrics & Gynecology, University of Texas Medical Branch
- Gideon Koren, MD, FRCPC, FACMT, Director, The Motherisk Program, The Hospital for Sick Children, Professor of Pediatrics, Pharmacology, Pharmacy and Medical Genetics, The University of Toronto, Professor of Medicine, Pediatrics and Physiology/Pharmacology and the Ivey Chair in Molecular Toxicology, The University of Western Ontario
- Jennifer R. Niebyl, MD, Professor & Vice-Chair, Department of Obstetrics & Gynecology, University of Iowa Hospitals and Clinics
Asked what prompted her to speak at the symposium on the state of NVP treatments, Dr. Niebyl stated, "It is big news that the FDA approved a new drug to address NVP. Because the drug will be available in the marketplace by the end of May, I think it’s very timely and important to educate OB-GYN practitioners about the treatment and how it is administered. Approval of the treatment is exciting, because controlled clinical trials showed benefits for many patients and the newly approved treatment has the best safety data of any drug that is used for this indication. I’m also looking forward to reviewing other treatments and the overall impact of NVP on the health of pregnant women."
Donations to the March of Dimes
Further contributing to the benefits of attending the symposium, the program’s organizers have pledged to make a $10 donation to the March of Dimes on behalf of each attendee. The March of Dimes is committed to helping mothers experience healthier pregnancies, and Metro New Orleans Division Board Member Jane C. Miller, MD, OB-GYN is pleased the symposium will both benefit pregnant women and help raise much-needed funding for the non-profit organization's mission. "In Louisiana each week,” Dr. Miller stated, "over 360 babies are born low birth weight or preterm, one of the highest in the nation. It is the mission of the March of Dimes to not only prevent birth defects but premature birth as well. Healthy mothers mean healthy babies. We are pleased to be associated with this educational event to help bring awareness to the health of expectant women.”
With an informative educational program on women’s health as well as the added benefit of contributing to the March of Dimes, it appears healthcare professionals planning to attend the "Nausea & Vomiting of Pregnancy: Cases for Pharmacological Consideration" symposium can expect the evening to be time well spent.
For more information about the symposium, contact Medavera President & CEO Laura McCaskill by email at Laura(at)medavera(dot)com or by phone at 417-890-9722.
1. American College of Obstetricians and Gynecologists. Nausea and vomiting of pregnancy. ACOG Practice Bulletin. 2004;52.
2. Niebyl JR. Nausea and vomiting in pregnancy. N Engl J Med. 2010;363(16):1544–1550.